Buprenorphine Patch, Extended Release
Product Images NDC 50742-376

Product Visual Gallery

This gallery contains 26 technical images submitted to the FDA as part of the official labeling for Buprenorphine (NDC 50742-376). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ingenus Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton-10mcg.jpg (Carton 10mcg)

Packaging label for Buprenorphine Transdermal System 10 mcg/hour by Ingenus Pharmaceuticals, LLC. The label indicates a transdermal patch for systemic delivery of 10 mcg per hour for seven days. The package contains 4 transdermal systems and 4 disposal units. It is intended for use in opioid-experienced patients only and includes storage instructions and dispensing precautions.*

FDA Label Image

Carton-15mcg.jpg (Carton 15mcg)

Packaging label for Buprenorphine Transdermal System 15 mcg/hour patch, extended-release, transdermal dosage form. The box indicates it contains 4 transdermal systems (patches) and one package of 4 disposal units. Labeler is Ingenus Pharmaceuticals, LLC. The label includes prescription-only status and opioid-use warnings.*

FDA Label Image

Carton-20mcg.jpg (Carton 20mcg)

Packaging label for Buprenorphine Transdermal System 20 mcg/hour, an extended-release transdermal patch. The label shows a carton containing 4 patches (4 transdermal systems) in one package of 4 disposal units. Manufactured by Ingenus Pharmaceuticals, LLC, the label includes a barcode, storage instructions, and a designated area to affix a pharmacy label. The product is intended for opioid-experienced patients only.*

FDA Label Image

Carton-5mcg.jpg (Carton 5mcg)

Packaging label for Buprenorphine Transdermal System 5 mcg/hour patch, extended-release transdermal system. The carton contains 4 transdermal systems and 4 disposal units. Distributed by Ingenus Pharmaceuticals, LLC. The label emphasizes the 5 mcg/hour dosage strength multiple times and includes areas for affixing pharmacy labels and medication guides.*

FDA Label Image

Carton-7.5mcg.jpg (Carton 7.5mcg)

Packaging label for Buprenorphine Transdermal System 7.5 mcg/hour extended-release patch by Ingenus Pharmaceuticals, LLC. The label mentions a package containing 4 transdermal systems and 4 disposal units, intended for use in opioid-experienced patients only. The label includes safety warnings and dosage form details for transdermal delivery.*

FDA Label Image

Fig1.jpg (Fig1)

An instructional diagram illustrating the layered structure of a Buprenorphine transdermal patch, extended release. The labeled layers include a backing layer, overlapping adhesive film, separating layer, drug/polymer adhesive matrix, and a peel-off release liner.*

FDA Label Image

Fig2.jpg (Fig2)

A line graph depicting buprenorphine plasma concentration (pg/mL) over time in days following administration of Buprenorphine TDS 10 mcg/hour every 7 days for three cycles (N=36). The chart shows concentration peaks and declines with indicated removal of the transdermal system at day 21, followed by a rapid decrease in concentration.*

FDA Label Image

Fig3.jpg (Fig3)

A line graph comparing the percentage of patients improved versus the percent of reduction/improvement in pain for Placebo and Buprenorphine TDS 10/20. The x-axis shows percent reduction/improvement in pain from >0% to 100%, and the y-axis shows the percentage of patients improved, ranging from 0% to 100%. Two lines represent Placebo (open circles) and Buprenorphine TDS 10/20 (solid squares), indicating higher patient improvement percentages with Buprenorphine TDS 10/20 across the range.*

FDA Label Image

Fig4.jpg (Fig4)

A line graph comparing the percentage of patients improved at various percent reductions or improvements in pain for Buprenorphine transdermal system (TDS) at 5 ug/h and 20 ug/h strengths. The x-axis represents percent of reduction/improvement in pain from >0% up to 100%, and the y-axis represents the percentage of patients improved, ranging from 0% to 100%. Two lines show that a higher percentage of patients improved at each level with the 20 ug/h strength compared to the 5 ug/h strength.*

FDA Label Image

Figa.jpg (Figa)

Illustration showing correct placement locations for a Buprenorphine transdermal patch on a human body. The diagram includes side, front, back, and raised-arm views, with patches applied on the upper arm, upper chest, upper back, and side torso areas.*

FDA Label Image

Figb.jpg (Figb)

An illustration showing the placement of two Buprenorphine transdermal patches applied on the upper back area of a human figure, indicating proper application sites for the extended-release patches.*

FDA Label Image

Figc.jpg (Figc)

An illustration labeled Figure C showing a person applying a transdermal patch to the left upper chest area. The image highlights the location and method for placing a Buprenorphine extended release transdermal patch.*

FDA Label Image

Figd.jpg (Figd)

An instructional diagram labeled Figure D showing hands cutting a rectangular patch with scissors. The patch appears to be a transdermal adhesive, consistent with a buprenorphine extended-release patch, demonstrating how to trim the patch before use.*

FDA Label Image

Fige.jpg (Fige)

An instructional diagram showing a Buprenorphine transdermal patch partially removed from its foil backing. The image labels the patch, foil backing, and foil handle, illustrating how to peel the patch from its packaging for application.*

FDA Label Image

Figf.jpg (Figf)

An instructional line drawing showing two hands applying or removing a protective backing from a transdermal patch, labeled as Figure F. The image demonstrates handling or preparation of the patch for use.*

FDA Label Image

Figg.jpg (Figg)

An instructional illustration showing a person holding a patch near the upper chest area, indicating placement of a buprenorphine transdermal patch on the body. The figure is labeled "Figure G."*

FDA Label Image

Figh.jpg (Figh)

An instructional illustration labeled as Figure H showing a simplified outline of a person applying a transdermal patch to the upper chest area. The person uses both hands for the application, with one hand holding the patch while the other hand is positioned on the chest.*

FDA Label Image

Figi.jpg (Figi)

An instructional illustration labeled Figure I showing a person applying a rectangular transdermal patch to the upper chest area, above the breast. The image is used to demonstrate the proper placement of a Buprenorphine transdermal patch.*

FDA Label Image

Figj.jpg (Figj)

An instructional illustration labeled 'Figure J' showing hands removing a protective liner from a Buprenorphine transdermal patch. The figure highlights an adhesive strip and a peel-away liner with text instructions visible on it, demonstrating the step to prepare the patch for application.*

FDA Label Image

Figk.jpg (Figk)

An instructional illustration labeled Figure K showing two hands holding and peeling apart a rectangular object, likely demonstrating how to open or handle a transdermal patch packaging for Buprenorphine extended-release patches.*

FDA Label Image

Figl.jpg (Figl)

An instructional illustration labeled "Figure L" showing hands peeling adhesive strips from a package containing a transdermal patch. The image demonstrates the proper removal of the patch's adhesive covering prior to application.*

FDA Label Image

Figm.jpg (Figm)

Illustration labeled Figure M showing two hands peeling back a protective layer from a rectangular patch. The patch appears to be an adhesive transdermal patch with text printed on its surface, demonstrating how to remove the backing for application.*

FDA Label Image

Fign.jpg (Fign)

An instructional illustration labeled Figure N showing a hand placing an item into a container, likely demonstrating proper disposal of the product or related materials.*

FDA Label Image

Figo.jpg (Figo)

An instructional line drawing showing a toilet with the lid and seat raised. A hand is depicted above the toilet, holding a square object, likely representing disposal of a medication patch or similar item into the toilet bowl, labeled as Figure 0.*

FDA Label Image

Structure.jpg (Structure)

Chemical structure diagram of Buprenorphine, showing its molecular framework with labeled functional groups and rings.*

FDA Label Image

Table1.jpg (Table1)

A dosing guideline chart for Buprenorphine transdermal system showing recommended starting doses based on previous opioid analgesic daily dose in oral morphine equivalent. It matches under 30 mg to 5 mcg/hour and 30-80 mg to 10 mcg/hour starting doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.